Clinical Trials
Early human trial
Plasma exchange lowered biological-age markers in a small placebo trial
Source: Aging Cell (Buck Institute)
What the study found
In a placebo-controlled study of 42 healthy adults over 50, therapeutic plasma exchange (TPE) was generally safe and improved 15 epigenetic clocks compared with placebo. Biweekly TPE plus intravenous immunoglobulin worked best, lowering estimated biological age by an average of about 2.6 years.
Why it matters for healthspan
It is the first multi-omics look at whether removing and replacing plasma shifts aging biomarkers in healthy people. The trial was small, randomized by entry date and single-blinded, measured surrogate markers rather than health outcomes, and was supported by a company whose members include study authors.
Evidence level
Early human trial · Clinical Trials
Source
Fuentealba M, Kiprov D, Schneider K, et al. Aging Cell. 2025;24(8):e70103. doi:10.1111/acel.70103
Educational summary curated by Farhan Tahir, MD, FACR. Not individual medical advice.
Primary source
Fuentealba M, Kiprov D, Schneider K, et al. Aging Cell. 2025;24(8):e70103. doi:10.1111/acel.70103